Department of Medicine, Stanford University, Stanford, CA, USA.
Department of Medicine, Georgetown University, Washington, DC, USA.
Lancet Microbe. 2022 May;3(5):e392-e398. doi: 10.1016/S2666-5247(21)00250-0. Epub 2022 Jan 19.
HIV-1 pol sequences from antiretroviral therapy (ART)-naive and ART-experienced people living with HIV-1 are fundamental to understanding the genetic correlates and epidemiology of HIV-1 drug resistance (HIVDR). To assess the public availability of HIV-1 pol sequences and ART histories of the individuals from whom sequenced viruses were obtained, we performed a systematic review of PubMed and GenBank for HIVDR studies published between 2010 and 2019 that reported HIV-1 pol sequences. 934 studies met inclusion criteria, including 461 studies of ART-naive adults, 407 of ART-experienced adults, and 66 of ART-naive and ART-experienced children. Sequences were available for 317 (68·8%) studies of ART-naive individuals, 190 (46·7%) of ART-experienced individuals, and 45 (68·2%) of children. Among ART-experienced individuals, sequences plus linked ART histories were available for 82 (20·1%) studies. Sequences were available for 21 (29·2%) of 72 clinical trials. Among journals publishing more than ten studies, the proportion with available sequences ranged from 8·3% to 86·9%. Strengthened implementation of data sharing policies is required to increase the number of studies with available HIVDR data to support the enterprise of global ART in the face of emerging HIVDR.
从从未接受过抗逆转录病毒疗法 (ART) 和接受过 ART 的艾滋病毒感染者中获取的 HIV-1 pol 序列,对于了解 HIV-1 耐药性 (HIVDR) 的遗传相关性和流行病学至关重要。为了评估从获得测序病毒的个体中获取的 HIV-1 pol 序列和 ART 史的公开可用性,我们对 2010 年至 2019 年间发表的报告 HIV-1 pol 序列的 HIVDR 研究进行了系统的 PubMed 和 GenBank 文献检索。934 项研究符合纳入标准,包括 461 项针对未接受过 ART 的成年人的研究、407 项针对接受过 ART 的成年人的研究和 66 项针对未接受过 ART 和接受过 ART 的儿童的研究。有 317 项(68.8%)未接受过 ART 的个体研究、190 项(46.7%)接受过 ART 的个体研究和 45 项(68.2%)儿童研究可获得序列。在接受过 ART 的个体中,有 82 项(20.1%)研究可获得序列和相关的 ART 史。有 21 项(29.2%)临床试验可获得序列。在发表超过 10 项研究的期刊中,有可用序列的比例范围为 8.3%至 86.9%。需要加强数据共享政策的实施,以增加具有可用 HIVDR 数据的研究数量,从而支持在出现新的 HIVDR 时进行全球 ART 事业。